H ypoxic pulmonary hypertension (HPH) is still a lifethreating disorder lack of effective agents. It is highly prevalent in advanced chronic obstructive pulmonary disease and high altitude hypoxia. With the increase of chronic obstructive pulmonary disease patients, the morbidity of HPH is rising. Although most of HPH is mild to moderate, a subpopulation (1%-4%) with grim prognosis present with severe pulmonary hypertension.
H ypoxic pulmonary hypertension (HPH) is still a lifethreating disorder lack of effective agents. It is highly prevalent in advanced chronic obstructive pulmonary disease and high altitude hypoxia. With the increase of chronic obstructive pulmonary disease patients, the morbidity of HPH is rising. Although most of HPH is mild to moderate, a subpopulation (1%-4%) with grim prognosis present with severe pulmonary hypertension. 1 Pharmacological agents moderately improve the symptoms and hemodynamic parameters of severe pulmonary hypertension, but none significantly reduces mortality. 2, 3 There is a pressing need to identify novel target to treat HPH.
One of the characteristics of HPH is the dramatic remodeling of pulmonary vascular adventitia. 4, 5 During the remodeling, pulmonary adventitial fibroblasts (PAFs) are highly activated and undergo phenotype switch characterized by excessive proliferation, migratory, and inflammatory activity. 6, 7 Therefore, inhibition of the aberrant activation of PAFs may reverse the remodeling process of pulmonary vascular adventitia and have therapeutic potential for HPH. 8 Increasing evidence shows that miRNAs, especially miR-29 family members, participate in the development of organ fibrosis via regulating the activation of fibroblasts. [9] [10] [11] Downregulation of miR-29 underlies transforming growth factor-β-mediated pulmonary fibrosis, and overexpression of miR-29 inhibits bleomycin-induced pulmonary fibrosis. 12 Although PAFs in HPH undergo the similar activated phenotype to that in lung fibrosis, 6 the role of miR-29 family member in the hypoxia-induced activation of PAFs and the development of HPH is not known. On the other hand, hypoxia-inducible factor-1α (HIF-1α), a key transcription factor mediating cellular response to hypoxia, and Smad3, which can inhibit miR-29 expression in organ fibrosis, are interdependent in hypoxia. [13] [14] [15] [16] Therefore, HIF-1α and Smad3 may be jointly involved in the regulation of miR-29 in the activation of PAFs in hypoxia.
The present study explored the effects of miR-29a in the activation of PAFs in hypoxia and the therapeutic potential in HPH. The results show that miR-29a-3p plays a key role in hypoxia-induced activation of PAFs and has protective effects in HPH in rats.
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Materials and Methods
For additional details, please see the online-only Data Supplement.
Vector Construction and Virus Production
The rat pre-miR-29a was synthesized, annealed, cloned to construct adeno-associated virus (AAV) vector. The constructed AAV-miR-29a or control vector was transfected into 293AAV cells to package AAV serotypes 5 (AVV5-miR-29a and AAV5-control).
Animal Experiments
Protocols were approved by the Animal Care and Use Committee of the Fourth Military Medical University. Rats were randomly divided into 4 groups (nomoxia+AAV5-control, normoxia+AVV5-miR-29a, hypoxia+AAV5-control, and hypoxia+ AAV5-miR-29a) and maintained in normoxia (21% O 2 ) or hypobaric hypoxia (10% O 2 ) for 4 (preventive experiment) or 6 (therapeutic experiment) weeks. A double (at day-0 and day-14 after hypoxia, preventive experiment) or a single (at day-28 after hypoxia, therapeutic experiment) intratracheal instillation of AAV5-miR-29a or AAV5-control (1×10 12 vg/kg/each instillation) were given. The right ventricle systolic pressure (RVSP) was measured as the indicator of pulmonary artery pressure.
Statistical Analysis
All values were presented as means±SD. The statistical differences between groups were evaluated by 1-way analysis of variance, followed by Bonferroni's test for multiple comparisons.
Results

Hypoxia Downregulated the Expression of miR-29a-3p in PAFs in HIF-1α/Smad3-Associated Pathway
We first examined the expression profiles of miR-29a/b family members in the pulmonary adventitia isolated from HPH rats and in PAFs cultured in hypoxia via real-time polymerase chain reaction. Figure 1A and 1B shows the profiles and the normalized levels of the miR-29a/b in pulmonary adventitia from HPH rats. Significant downregulation of miR-29a-3p, miR-29a-5p, and miR-29b-5p was seen; moreover, miR29a-3p decreased most by >30-folds. Similar results were seen in PAFs cultured in hypoxia ( Figure 1C and 1D ). So we chose miR-29a-3p as the representative of miR-29a/b family members in the following studies.
Next, we determined whether HIF-1α and Smad3 jointly mediated the hypoxia-induced reduction of miR-29a-3p. The expression of HIF-1α protein, the total protein of Smad3, and the phosphorylation of Smad3 significantly increased in PAFs in hypoxia ( Figure S1A -S1D in the online-only Data Supplement). Knockdown of HIF-1α or Smad3 with specific siRNA markedly reversed the hypoxia-induced reduction of miR-29a-3p in PAFs; however, the control sequence had no such effect ( Figure S1E and S1F). Knockdown of HIF-1α also significantly decreased the mRNA ( Figure S1G ) and the total and phosphorylated protein (Figure S1H-S1J) of Smad3 in PAFs in hypoxia. These results suggest that miR-29a-3p is downregulated in HIF-1α/Smad3-associated pathway in PAFs in hypoxia.
Role of miR-29a-3p in the Hypoxia-Promoted Proliferation and Migration of PAFs
Then we explored the role of miR-29a-3p in hypoxia-promoted proliferation and migration of PAFs. Hypoxia significantly accelerated the proliferation of PAFs by ≈25%. The mimic of miR-29a-3p significantly inhibited the hypoxia-induced proliferation ( Figure 2A ). The inhibitor did not further increase the proliferation of PAFs in hypoxia, but it significantly accelerated the proliferation of PAFs in normoxia by ≈30% ( Figure 2B ), suggesting that miR-29a-3p inhibitor mimicked The representative migration results were shown in Figure 2C and 2D. Hypoxia promoted the migration of PAFs; miR-29a-3p mimic significantly inhibited the migration of PAFs both in normoxia and in hypoxia ( Figure 2C ). However, miR-29a-3p inhibitor only promoted the migration of PAFs in normoxia ( Figure 2D ), suggesting it mimicked the effect of hypoxia on the migration of PAFs in normoxia. These results showed that the downregulation of miR-29a-3p underlay the promotion effects of hypoxia on the proliferation and migration of PAFs.
Role of miR-29a-3p in the Secretion of PAFs in Hypoxia
We explored the role of miR-29a-3p in the secretion of PAFs in hypoxia. Hypoxia significantly increased the secretion of transforming growth factor-β, endothelin-1, and platelet-derived growth factor in PAFs; miR-29a-3p mimic significantly inhibited the hypoxia-enhanced secretion of these cytokines ( Figure 3A-3C ). However, miR-29a-3p inhibitor significantly promoted the secretion of transforming growth factor-β, endothelin-1, and platelet-derived growth factor in PAFs in normoxia ( Figure 3D-3F) , mimicking the effects of hypoxia on the secretion of PAFs. These results showed that 
Role of miR-29a-3p in the Activation PhenotypeAssociated Proteins Expression of PAFs in Hypoxia
The expression of activation phenotype-associated proteins, such as α-SMA and Col1A1, is one of the important characters of activated PAFs; therefore, we explored the role of miR-29a-3p in the expression of α-SMA and Col1A1 in PAFs in hypoxia. Hypoxia significantly increased the expression of α-SMA and Col1A1 in PAFs at both the mRNA and the protein levels, whereas miR-29a-3p mimic significantly inhibited the hypoxia-induced expression of α-SMA and Col1A1 in PAFs ( Figure S2A -S2E). Moreover, miR-29a-3p inhibitor mimicked the effects of hypoxia: significantly increased expression of α-SMA and Col1A1 in PAFs in normoxia ( Figure S2F -S2J). These data indicated that the reduction of miR-29a-3p played a key role in the increased expression of α-SMA and Col1A1 in PAFs in hypoxia.
Preventive and Therapeutic Effects of miR-29a on HPH In Vivo
We further investigated the preventive effects of miR-29a, which can be processed into miR-29a-3p and miR-29a-5p in the transduced cells, on HPH in rats via AAV5 gene transfer. AAV5-miR-29a was preventively administrated at day-0 and day-14 after hypoxia, and the rats were kept in hypoxia for total 4 weeks. Figure 4A and 4B showed that hypoxia for 4 weeks significantly increased the RVSP from 22.6±4.2 to 40.9±7.6 mm Hg and right ventricle hypertrophy index from 0.24±0.03 to 0.39±0.07, respectively, whereas preventive administration of AAV5-miR-29a significantly decreased the RVSP from 40.9±7.6 to 30.3±6.1 mm Hg and right ventricle hypertrophy index from 0.39±0.07 to 0.28±0.05, respectively (all P<0.05; n=6). The representative hematoxylin and eosin staining of lung tissue and the summarized data of MT% (percent medial wall thickness) and MA% (percent medial wall area) of pulmonary artery are shown in Figure 4C -4E, respectively, which showed that hypoxia significantly increased MT% from 16.6%±3.6% to 55.0%±8.0% and MA% from 27.6%±3.2% to 79.7%±8.6%, whereas AAV-miR-29a significantly prevented the hypoxiainduced increase of MT% from 55.0%±8.0% to 26.6%±5.0% and MA% from 79.7%±8.6% to 45.6%±6.2% (all P<0.05, n=60).
To evaluate the therapeutic effects of miR-29a on the HPH, AAV5-miR-29a was administrated 4 weeks after hypoxia and then the rats were kept in hypoxia for another 2 weeks. Figure 5A and 5B shows that hypoxia for 6 weeks significantly increased the RVSP from 22.9±4.2 to 42.8±6.6 mm Hg and right ventricle hypertrophy index from 0.22±0.04 to 0.39±0.09, respectively, whereas AAV5-miR-29a treatment significantly reduced the increased RVSP from 42.8±6.6 to 35.0±4.2 mm Hg and RVHI from 0.39±0.09 to 0.30±0.05, respectively (all P<0.05; n=6). Figure 5C -5E shows the representative hematoxylin and eosin staining of lung tissue and the summarized data of MT% and MA% of pulmonary artery. Hypoxia significantly increased MT% from 16.6%±3.6% to 58.0%±8.0% and MA% from 26.6%±3.2% to 83.7%±8.6%, respectively, that AAV5-miR-29a treatment significantly reduced the hypoxia-induced increase of MT% from 58.0%±8.0% to 34.0%±5.0% and MA% from 83.7%±8.6% to 55.6%±6.0% (all P<0.05; n=60). However, preventively or therapeutic administration of AAV5 control had no such effects (Figures 4 and 5A-5E ). In addition, preventively or therapeutic administration of AAV5-miR29a had . These results demonstrated that miR-29a-3p had preventive and therapeutic effects on HPH in rats.
Furthermore, we measured the expression of miR-29a-3p in the pulmonary adventitia isolated from the rats administrated with AAV5-miR-29a or AAV5-control. Figures 4 and 5F show that hypoxia significantly decreased the expression of miR29a-3p by >31-folds in pulmonary adventitia, similar to the result in Figure 1 . Both preventive and therapeutic administration of AAV5-miR-29a significantly increased the expression of miR29a-3p in pulmonary adventitia in HPH and normal rats. However, administration of AAV5-control had no effect on the expression of miR-29-3p.
Discussion
In this study, we showed that hypoxia downregulated the expression of miR-29a-3p in PAFs via HIF-1α/Smad3-associated pathway. Loss of miR-29a-3p mediated the hypoxia-induced PAFs activation and phenotype. In vitro, miR-29a-3p mimic reversed, but its inhibitor mimicked, the effects of hypoxia on PAFs. Moreover, preventive or therapeutic transduction of miR-29a-3p markedly ameliorated HPH in rats. The present study first demonstrates that miR29a-3p regulates the activation and phenotype switch of PAFs in hypoxia and has the preventative and therapeutic potential in HPH.
Fibroblasts are activated in both organ fibrosis and hypoxic pulmonary artery remodeling. Activated fibroblasts show aberrant phenotype of excessive proliferation, migratory, secretion, fibrotic, and inflammatory activity. 7 Increasing evidence suggests a key role of miRNAs in the fibroblasts activation and organ fibrosis. [9] [10] [11] [12] [13] 17 The present study added novel evidence that miR-29a-3p had a protective role in HPH. This was supported by the data that HPH was associated with a marked reduction of miR-29a-3p in pulmonary artery adventitia, and overexpression of miR-29a-3p ameliorated HPH. The result from in vivo experiments is somewhat striking, just as previous study showed that overexpressing miR-29b prevented Angiotensin II-mediated cardiac fibrosis, restoration of miR-29b in hypertensive heart could block progressive cardiac fibrosis and improve cardiac dysfunction. 13 However, considering that AAV5 can consistently express target gene miR29a for >2 weeks and the broad biological effects of miR-29a, the results are believable. Moreover, in vitro, the mimic of miR-29a-3p significantly inhibited the hypoxia-induced aberrant proliferation, migration, secretion of transforming growth factor-β, endothelin-1, and platelet-derived growth factor, and expression of α-SMA and Col1A1, all of which are the characteristic phenotypes of activated PAFs. Conversely, the inhibitor of miR29a-3p mimicked the effects of hypoxia on PAFs (Figures 2  and 3 ; Figure S1 ). Therefore, the in vitro and in vivo data suggest that inhibition of PAFs activation underlies the protective effect of miR-29a-3p on HPH.
Recently, Li et al 18 reported that the natural agent, isoflavone, could demethylate the methylation sites in the promoter of miR-29a, leading to the upregulation of miR-29a. Interestingly, isoflavone (genistein) is previously found to attenuate/reverse pulmonary hypertension in rats. [19] [20] [21] Whether isoflavone exerted the benefit effect on pulmonary hypertension partly via upregulation of miR-29a is not known.
This study revealed that hypoxia reduced miR-29a-3p in PAFs via HIF-1α/Smad3-associated pathway. It is supported by the findings that HIF-1α and Smad3 were significantly increased in PAFs in hypoxia, concomitant with the reduction of miR-29a-3p, and that knockdown of HIF-1α or Smad3 inhibited hypoxia-induced reduction of miR-29a-3p. Moreover, knockdown of HIF-1α also decreased the expression of Smad3 in PAFs in hypoxia, suggesting that Smad3 may be the downstream effector of HIF-1α. These results are consistent with those of previous studies that showed that there is interdependence of HIF-α and Smad3 signaling in hypoxia. 15, 16 However, the detailed mechanism for the regulation of HIF-1a and Smad3 on miR-29a-3p in PAFs in hypoxia is still to be explored.
In the development of HPH, pulmonary artery smooth muscle cells and pulmonary endothelial cells also participate in the remodeling of pulmonary artery. 13, 22 Previous studies showed that miRNAs regulated the phenotype of pulmonary artery smooth muscle cells in hypoxia and mediated the hypoxia-promoted proliferation of pulmonary endothelial cells. [23] [24] [25] In addition, decrease of miR-124 contributes to the activation of PAFs from severe pulmonary hypertension patient. 6 In this study, we only focused on the role of miR-29a-3p in the activation of PAFs in hypoxia and the hypoxic remodeling of pulmonary artery and found its protection in HPH. It must be in mind the species difference and the limitations of chronically hypoxic rats as models of human pulmonary hypertension. 2 Future works are needed to examine the role of miR-29a-3p in the phenotype regulation of pulmonary artery smooth muscle cells and pulmonary endothelial cells in hypoxic pulmonary vascular remodeling, especially in human PAFs and HPH patients, before it is translated to clinic.
Perspectives
HPH is still a life-threating disorder characterized by the dramatic remodeling of pulmonary vascular adventitia caused by hypoxia-induced aberrant activation of PAFs. This study showed that hypoxia-induced activation of PAFs was accompanied with the drastic decrease of miR-29a-3p. In vitro, miR-29a-3p mimic inhibited the hypoxia-induced proliferation, migration, and secretion of PAFs, suppressed hypoxiainduced expression of activation-associated proteins in PAFs; moreover, miR-29a-3p inhibitor mimicked the effects of hypoxia on PAFs. Preventative or therapeutic administration of miR-29a-3p significantly ameliorated pulmonary vascular remodeling and pulmonary hypertension in HPH rats. These results demonstrate that miR-29a-3p regulates the hypoxiainduced activation and phenotype of PAFs and may be a treatment target for HPH. 
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What Is New?
• Hypoxia-induced activation of pulmonary adventitial fibroblasts (PAFs) was accompanied by the drastic decrease of miR-29a-3p. miR-29a-3p inhibited hypoxia-induced activation of PAFs in vitro and ameliorated hypoxic pulmonary hypertension in vivo.
What Is Relevant?
• Hypoxic pulmonary hypertension is one type of pulmonary hypertension characterized by pulmonary vascular remodeling and increased pulmonary artery pressure. Hypoxia-induced PAF activation is key in pulmonary vascular remodeling. Inhibition of aberrant PAF activation may reverse pulmonary vascular remodeling. The role of miR-29a-3p in hypoxia-induced activation of PAFs and hypoxic pulmonary hypertension is not known. Chongqing, China 17 18 Running title: miR-29a-3p attenuates pulmonary hypertension 19 20 21 Correspondence should be addressed to: Vector construction and virus production 5 The rat pre-miR-29a complementary DNA was synthesized (Sangon, Shanghai, China) (forward: concentrated. The ultimate virus titer (vector genomes/ml) for AAV5-miR-29a and AAV5-control is 16 7.5×10 12 and 1.0×10 13 respectively. 17 18 Animal experiments 19 All the experiments were approved by the Animal Care and Use Committee of the Fourth Military
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Medical University and complied with the Declaration of the National Institutes of Health Guide for 21 Care and Use of Laboratory Animals. All animals were maintained in a 12 to 12 hours light-dark 22 cycle in an air-conditioned room (25 °C) and had free access to food and water. by exsanguination, and the heart and lung were harvested for subsequent experiments. Melbourne, VIC, Australia) at 37°C in 95% O 2 ,5%CO 2 . Fibroblasts cell grew from the plants about 13 5 days. They were passaged and cultured in in RPMI 1640 medium with 10% FBS. The three to six 14 passages were used for the following experiments. 15 16 Cell proliferation assay 17 PAFs were cultured in 24-well plate to 40% confluence, then transfected with 10 nM miR-29a-3p 18 mimic, 50 nM miR-29a-3p inhibitor or corresponding amounts of negative controls (all from 19 Ribobio, Guangzhou, China, the catalog number were shown in Table S1 ). After 6 hours, the 20 medium was changed and the cells were cultured for another 24h. Then PAFs were passaged and 21 used for cell proliferation assay and cell cycle analysis. 22 23 PAFs proliferation was measured by 3 -(4, 5 -dimethylthiazal -2 -yl) -2, 5 - RiboBio, Guangzhou, China) and the primers for α-SMA and Col1A1 were shown in Table S1 . The 20 ratio of the mRNA of interest was normalized with U6 (for miR-29a-b) or β-actin (for Col1A1, 21 α-SMA). 22 23 Western blot analysis 24 The total lysate was obtained from the harvested cells or lung arteries, and used for the extraction of 25 protein according to the instructions of Total Protein Extraction Kit (Millipore, Bedford, MA, USA).
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The lung arteries (the first-to the third-division) were harvested under a light microscope with a 27 forceps. The adventitia is carefully isolated from arteries under a high-magnification microscope 28 (Leica, Narishige Micromanipulator, Wetzlar, Germany).
29
The protein concentration was determined with BCA protein assay kit (Bio-Rad, Hercules, CA, by one-way analysis of variance (ANOVA), followed by Bonferroni's test for multiple comparisons. 
